|
Post by JHam on Jul 30, 2014 18:41:31 GMT
I guess when I say shady, I meant it seems like a sneaky way to increase the A/S without having to do a proxy to "raise the A/S". I have a good feeling lots of novice investors get taken by this strategy if it is indeed one that's widely used. Using this generic example: O/S: 800,000 A/S: 200,000 After 20:1 R/S O/S: 40,000 A/S: 200,000 This would royally piss me off as an existing shareholder. Yeah, it is unnecessary in my opinion unless they really are planning to do some more heavy dilution. But then again, even then it is a bit overkill.
|
|
|
Post by JHam on Jul 30, 2014 18:45:35 GMT
P.S. The reason for the uptick today is because Maxim initiated coverage with a target price of $3.00.
Obviously we know the history of Maxim and their target prices, so I don't think it is anything to get too excited about. I wouldn't not be surprised the pps come back down to earth here by the end of the day today/tomorrow.
|
|
|
Post by RLC on Jul 30, 2014 19:15:24 GMT
P.S. The reason for the uptick today is because Maxim initiated coverage with a target price of $3.00. Obviously we know the history of Maxim and their target prices, so I don't think it is anything to get too excited about. I wouldn't not be surprised the pps come back down to earth here by the end of the day today/tomorrow. Thanks for the note JHam... I didn't catch that about Maxim this morning. Good ol' Maxim!
|
|
|
Post by JHam on Aug 4, 2014 9:45:32 GMT
I finally had a chance to go back over my notes and re-listen to the part of the call in June that talked about publishing data results. Here is the quote from the call as well as the link to the call: (around 2:30) www.veidan.co.il/en/files/IRArchive/Brainstorm%20Cell%20Therapeutics%20Ltd.%20Q1%202014%20Conference%20Call%2010.06.14.mp3"On the interim results, we cannot go into more detail than what we published in the PR, for various reasons. First of all, the principal investigator is writing, preparing a paper to be published in a leading journal and therefore he's not publishing the set of slides. And we were able to publish only what he allowed us. The interim company report will be done only when the finalization of the follow up of the two subjects that we're still following up. We believe that will be in the end of August. But we are very encouraged and very happy with the results. We've seen they are robust and better than anticipated."It's a bit difficult to connect the dots here. It looks as though interim data will be published and not final results. What is the company report? If the trial investigator is waiting for the data on the last two patients then the journal publication could take a bit longer (maybe fall?). If he is not waiting for that data, then I think it could be sooner.
|
|
|
Post by selluwud on Aug 15, 2014 19:29:06 GMT
I guess when I say shady, I meant it seems like a sneaky way to increase the A/S without having to do a proxy to "raise the A/S". I have a good feeling lots of novice investors get taken by this strategy if it is indeed one that's widely used. Using this generic example: O/S: 800,000 A/S: 200,000 After 20:1 R/S O/S: 40,000 A/S: 200,000 This would royally piss me off as an existing shareholder. I don't see that the A/S were included in the R/S in this 8K filed today. It is for issued and outstanding shares 1 / 10-20 reverse split. biz.yahoo.com/e/140815/bcli8-k.html
|
|
|
Post by JHam on Aug 22, 2014 6:40:36 GMT
I guess when I say shady, I meant it seems like a sneaky way to increase the A/S without having to do a proxy to "raise the A/S". I have a good feeling lots of novice investors get taken by this strategy if it is indeed one that's widely used. Using this generic example: O/S: 800,000 A/S: 200,000 After 20:1 R/S O/S: 40,000 A/S: 200,000 This would royally piss me off as an existing shareholder. I don't see that the A/S were included in the R/S in this 8K filed today. It is for issued and outstanding shares 1 / 10-20 reverse split. biz.yahoo.com/e/140815/bcli8-k.htmlI think we can conclude now that simply the a/s will not be split along with the o/s. Just for the record, here is the current share structure: Common stock of $0.00005 par value - Authorized: 800,000,000 shares at June 30, 2014 and December 31, 2013; Issued and outstanding: 225,472,618 and 176,263,587 shares at June 30, 2014 and December 31, 2013 respectively.That is a lot of available shares and it seems odd that they wouldn't r/s these as well. After thinking about it more though, a 1:20 r/s would leave them with a little over 11M shares outstanding. By r/sing the a/s at the same ratio, that would *only* give BCLI 40M shares to work with for future capital raises or what not. As much as I hate to see them dilute again, I find it very improbable that BCLI will head into the future with only 11M shares outstanding. I guess they could have issued a proxy to r/s the a/s at a separate ratio than the o/s. Not sure why they didn't do that. Nonetheless, while I do expect some dilution after the r/s and up-list that is on the horizon, I do not expect them to do something so drastic that it would wipeout existing shareholders. (We'll see if I eventually eat my words on this). That said, in interest of preserving capital and locking in some profits, I did take half of my position off the table between $.32-.29 over the span of a few days a couple weeks ago. I will be looking to add again if it heads south of my cost average ($.26), or as we get closer to these upcoming catalysts.
|
|
|
Post by JHam on Sept 5, 2014 18:48:36 GMT
BCLI is getting a bit beat up today. May start buying again if this keeps up.
|
|
|
Post by lcd on Sept 5, 2014 18:53:41 GMT
Jham,
I was thinking the same thing. I already have more than I should but I put some ACTCD on the block at $9.25 and if it hits, I might turn it around on BCLI.
|
|
|
Post by JHam on Sept 5, 2014 19:07:05 GMT
Jham, I was thinking the same thing. I already have more than I should but I put some ACTCD on the block at $9.25 and if it hits, I might turn it around on BCLI. I hear ya. I totally plan on taking some ACTC and FOLD profits and putting them into BCLI. I'll definitely have my eye on this for the next few days.
|
|
|
Post by RLC on Sept 5, 2014 19:27:25 GMT
BCLI is getting a bit beat up today. May start buying again if this keeps up. Was just coming to the forum to post this same thing. Anything under $0.30 with this one has me contemplating a purchase. I'm still a little disappointed in that the company doesn't intend to reverse split the A/S at the same proportion as the O/S, but I guess they would have needed to raise the A/S without doing this so it seemed to be the lesser of two evils. Really like the hire of Tony Fiorino and feel like the company is at a similar type of inflection point as ACTC in which a large amount of value creation is (probably) forthcoming. And for a small-cap biotech in the regenerative medicine space, I was amazed to see the following from this scum: @adamfeuerstein
I have no idea if $BCLI has figured out the stem cell secret sauce for success, but new CEO Tony Fiorino is a fantastic hire.
|
|
|
Post by lcd on Sept 5, 2014 19:58:28 GMT
The price keeps flirting with my $9.25 offer but it won't happen in time today for me to turn around and buy more BCLI today. Definitely interested to see where the pps goes on this one next week. I am in the red but comfortable with it until we get more news. RLC, I know Adam Feuerstein isn't a favorite among many biotech investors, especially those dabbling in the OTC, but I like him. He is usually correct and has good taste in music and beer.
|
|
|
Post by lcd on Sept 22, 2014 14:49:24 GMT
Nice jump in price this morning on decent volume. I think they are getting close to qualifying for the uplist if they stay above $3 for the next few days, right? Not sure if this is Lebovitz or some other insider buying, but hopefully some good news is coming this week.
|
|
|
Post by JHam on Sept 22, 2014 15:13:25 GMT
Nice jump in price this morning on decent volume. I think they are getting close to qualifying for the uplist if they stay above $3 for the next few days, right? Not sure if this is Lebovitz or some other insider buying, but hopefully some good news is coming this week. If my math is right, 5 trading days from Tues. Sept. 16, when the r/s was made official, would be today. If they make it through today they should be good to go.
|
|
|
Post by JHam on Oct 1, 2014 8:58:42 GMT
Just thinking out loud here.
The company said this in their last 10Q:
"These two patients were treated at the beginning of the second quarter of 2014. The complete and final statistical analysis of the Phase IIa data is expected to be available after 6 months of follow up with the patients."
That would take us to mid-Oct for the earliest final Phase I/IIa data release. I believe Lebovits mentioned they were looking to publish the data in a peer reviewed journal. If that's the case it could take a little longer. Whether they go the journal route, or just simply release a paper, I would not be surprised (and actually would expect) to see them use that opportunity to raise cash. They probably have around $10M in cash at the moment. That will get them through Phase II, but if they plan on going after some other indications (as was mentioned at Rodman & Renshaw), starting an expanded Phase study (re-dosing phase), and expanding operations in any way, they are going to need some money.
Parkinson's makes the most sense for the next indication. Parkinson's is what NurOwn was originally developed for. They decided to go with ALS first because that trial was apparently much cheaper. They completed the Parkinson's pre-clinical work almost a decade ago and since ALS is basically acting as a proof-of-concept trial for a treatment that was originally developed for Parkinson's, I think that is what they will target next.
It will not be cheap though, so I imagine it will be a pretty big raise. Complete speculation on my part, but the potential good news is that I think there is a very good chance that BCLI will be able to skip Phase I and start their next indication (especially if it is Parkinson's) from a pivotal trial. There is no need for them to have to prove safety and tolerability for a product that they have already proven safety and tolerability for, and I think the FDA is starting to show they are more open to this.
|
|
|
Post by selluwud on Oct 6, 2014 13:40:37 GMT
|
|
|
Post by JHam on Oct 6, 2014 13:49:43 GMT
Thanks for posting. Glad to see that things are running right on schedule.
|
|
|
Post by lcd on Oct 6, 2014 16:29:17 GMT
The market sure doesn't seem excited about the news. BCLI is at $3.80 right now. I would buy more but I think I own more than enough.
|
|
|
Post by JHam on Oct 15, 2014 15:34:40 GMT
Took some ACT profits and also added more BCLI (ONCS too). No problem adding more with the market cap hovering at $53M. That would be $.23 pre-r/s.
|
|
|
Post by JHam on Oct 17, 2014 18:32:40 GMT
I added some more today at $3.94. There is for sure some volatility to come, but I just like how things are unfolding with this company and I really like the CEO. I am also looking ahead to the data release by the end of the year.
|
|
|
Post by JHam on Oct 20, 2014 14:23:28 GMT
Just added another chunk at $3.83.
|
|